The chief medical officer of NMD Pharma provided perspective on a newly launched phase 2 study assessing NMD670, a first-in-class neuromuscular transmission enhancer, in patients with spinal muscular atrophy type 3. [WATCH TIME: 5 minutes]
Jorge Quiroz, MD, MBA
Advertisement
Articles by Jorge Quiroz, MD, MBA
The chief medical officer of NMD Pharma shed light on a newly announced phase 2 study assessing NMD670, a neuromuscular transmission enhancer, for patients with spinal muscular atrophy. [WATCH TIME: 4 minutes]
Advertisement
Latest Updated Articles
Mechanism of Action of Investigational Agent NMD670 for SMA: Jorge Quiroz, MD, MBAPublished: March 5th 2024 | Updated:
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Parkinson Agent Tavapadon Shows Continued Efficacy, Safety in Phase 3 TEMPO-4 Trial
2
Elecsys pTau181 Test Cleared, Tividenofusp Alfa PDUFA Pushed Back, Phase 4 LOTUS Study Highlights Real-World Benefit of Trofinetide
3
Ruptured vs Unruptured Aneurysms: Practical Decision Making with Guilherme Dabus, MD
4
Bilateral MR-Guided Focused Ultrasound Shows Benefit for Managing Parkinson Motor Complications in Phase 3 Trial
5
